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发现 Gab2 蛋白表达与病人的年龄存在显著相关性，在小于 55 岁的病例中阳性




在胃癌预后检测标志物的筛选中，我们利用利用 Infinium Human Metyhlation
450 Beadchip 分析了三年内未复发（Long disease-free survival，LDFS）与一年内
复发 (Short disease-free survival SDFS) 胃癌病例中的 450，000 个甲基化位点，






















Since the concept of biomarkers has been proposed, tumor biomarkers (TBM) has
become a hot spot in the field of basic medical research. Based on the large number of clinical
samples,We study the prognostic biomarkers of breast cancer and gastric cancer with the use
of immunohistochemistry, methylation microarray analysis, real-time quantitative PCR and so
on to offer new ideas or new medical targets for the treatment of cancer.
Using of immunohistochemistry technology, we investigated the expression of tyrosine
phosphatase Shp2 and its chaperonin Gab2 in 141 cases of breast invasive ductal carcinoma
and analyzed the relationship between protein expression and pathological features. We found
Gab2 protein expression significantly correlated with the age of the patient, in which positive
expression rate was 84.6% in patients less than 55 years old and only 48.4% positive in 55
years and older cases(P = 0.0047). The phenomenon reveal that the difference of Gab2 protein
expression may be used as an important indicator of monitoring breast cancer. The result of
Shp2 protein expression in differernt control,such as tumor size, lymph node metastasis, the
expression of ER and PR, TNM stage,showed no correlation.
In the screening of gastric cancer prognostic biomarkers, we used the Infinium Human
Metyhlation 450 Beadchip to screen 450,000 methylation sites in Long disease-free
survival(LDFS) gastric cancer cases and Short disease-free survival(SDFS) gastric cancer
cases. We found that 558 sites exist methylation differences (P <0.05, t-test), which are
matched with 353 genes. Among these genes, we selected the top five genes(MDP1, LGALS8
DGKZ, CNNM4, B4GALNT2) which are significant different in methylation and analyzed
mRNA and protein expression of five genes in vivo and cellular level. The result shows that
the expression of mRNA and protein are different in vivo or vitro and methylation not always
leads to slience of genes. Although due to the fewer number of samples, the result is just a
simple coarse sieve and has limitations, it suggest that the methylation of genes in the























2.2 用于核酸生物标志物（Nucleic Acids Biomarkers）筛选的技术平台
..........................................................................................................................8
2.3 代谢产物和代谢组学（Metabolites and Metabolomics）................... 9



























Charpter 1 Introduction.................................................................................................. 1
Part 1 The current research status of tumor biomarkers.....................................1
1.1 The concept of tumor biomarker（TBM）............................................ 1
1.2 The problems in TBM research...............................................................2
1.3 The guidance of TBM discovery.............................................................4
Part 2 The technology platform in TBM screening............................................5
2.1 Screening Protein Biomarkers’ technology.............................................5
2.2 Screening Nucleic Acids Biomarkers’ technology..................................8
2.3 Metabolites and Metabolomics............................................................... 9
Part 3 The potential of DNAmethylation as a tumor biomarker..................... 10
3.1 Mechanisms to Establish and Maintain DNAMethylation Status........11
3.2 Relationship between Hypermethylated Genes and Tumorigenesis..... 13
3.3 Methods for Identifying Genes with Cancer-Specific DNA Methylation
........................................................................................................................14
3.4 DNAMethylation as a Biomarker.........................................................15
Part 4 Significance of our research.................................................................. 17
Charpter 2 Methods and Materials............................................................................19
Charpter 3 Results and Analysis............................................................................... 23
Part 1 Shp2 and Gab2 expression in breast cancer tissue.................................. 23
Part 2 Epigenetics research in recurrence of gastric cancer .............................28


























































摘自：Michael A. Tainsky, Ph.D. Genomic and Proteomic Biomarkers for Cancer: A Multitude of Opportunities.







































多个 TBM 双管齐下保证检测的准确性，但各 TBM 的灵敏度和特异性的平衡就
成了一个难题，因为增加灵敏度可能使得特异性降低。
最后，TBM 从基础研究到临床应用也是一个难题。用 PubMed 搜索 cancer
和 biomarker 关键词，可搜索出 2010年共有 15，000篇发表的文章，其中有 1100




摘自：Ludwig JA,Weinstein JN.Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer
2005;5:845–856.
图 1-2 生物标志物文章发表数量与通过 FDA 认证生物标志物数量
注 释：Number of publications under Medline heading “biomarker” (squares) and text word “biomarker”(circles)
and number of plasma-protein markers approved by the US Food and Drug Administration (FDA) (triangles) each







































































































摘自：Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nature






























抗体微阵列的原理类似于 highly parallel ELISAs，都是在复杂复数矩阵对多





















































在筛选具有临床意义的 DNA 序列变异已占有一席之地。使用 DNA 序列诊断标






















构的约 70-90 bp 的单链 RNA 前体经过 Dicer 酶加工后生成。其在细胞内具有多
种重要的调节作用，包括调控基因的表观遗传学修饰、表达蛋白的转录后翻译修
饰。类似 mRNA 分析的微阵列技术可以用于分析所有已知的 miRNAs，用于
miRNA分析的RNA样本必须包括小分子 RNAs，利用定量 RT-PCR分析miRNAs
可以实现 miRNAs标志物的标准化临床应用。通常使用阵列技术来筛选表达水平
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